ESC 365 - Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial

ESC Professional Premium Access

Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial

Session: Smaller trials: cardiac function and remodelling

Topic: Myocardial Disease

Speaker: Doctor C. Chin (Singapore, SG)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Calvin Chin

National Heart Centre Singapore, Singapore (Singapore)

2 presentations

1 follower

4 more presentations in this session

Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI)

Speaker: Professor T. Marwick (Melbourne, AU)

Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial

Speaker: Associate Professor S. Prabhu (Melbourne, AU)

Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction

Speaker: Doctor J. Carberry (Glasgow, GB)

Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.

Speaker: Doctor Y. Hsu (Tainan, TW)

Access the full session

Smaller trials: cardiac function and remodelling

Speakers: Doctor C. Chin, Professor T. Marwick, Associate Professor S. Prabhu, Doctor J. Carberry, Doctor Y. Hsu

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources